Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$0.9 - $1.17 $11,700 - $15,209	13,000 New	13,000 $13,000
Q4 2023 Feb 14, 2024	SELL	$1.34 - $1.85 $536 - $740	-400 Reduced 1.94%	20,200 $35,000
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.02 $35,462 - $48,076	-23,800 Reduced 53.6%	20,600 $34,000
Q2 2023 Aug 11, 2023	SELL	$2.0 - $3.36 $47,400 - $79,632	-23,700 Reduced 34.8%	44,400 $88,000
Q1 2023 May 16, 2023	BUY	$1.37 - $2.16 $2,603 - $4,104	1,900 Added 2.87%	68,100 $143,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $1.37 $16,700 - $22,879	-16,700 Reduced 20.14%	66,200 $90,000
Q3 2022 Nov 14, 2022	BUY	$1.03 - $1.24 $12,360 - $14,880	12,000 Added 16.93%	82,900 $86,000

3.54M

61.1K

36.2K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $84.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.